Fig. 5

ATOR-1015 localizes to the tumor and induces anti-tumor responses. (a) Homozygous hOX40tg mice were inoculated with MC38 cells day 0 and treated ip on days 7, 10 and 13 with antibodies (248 μg for bsAbs or 200 μg for mAbs) as indicated. Tumor volume in mice treated with ATOR-1015, surrogate anti-CTLA-4 antibodies (9D9 and 9H10) or vehicle (n = 7–10). (b-c) Tumor volume and survival after treatment with ATOR-1015, monotargeting anti-OX40 and anti-CTLA-4 antibodies or vehicle (n = 25–26). (d, e) Mice were treated once with ATOR-1015, monotargeting anti-OX40 and anti-CTLA-4 antibodies, IgG1 control or vehicle on day 17. Twenty-four hours later, tumors and spleens were collected and the level of hIgG⁺ cells was quantified by flow cytometry. Data show the percentage of hIgG⁺ cells out of live CD45⁺ cells (n = 5–10). All data presented as mean ± SEM. Statistical differences were analyzed using Mann-Whitney, two-tailed test, except survival that was analyzed using Kaplan-Meier, Log-Rank (*, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001). n equals the number of mice